



Between April and June, 68 participants, recruited from Hobart, Tasmania, were interviewed.



28 years




56%


Male

Median age and per cent who identified as male.

Unemployed 44%
Current students 24%
Full time work 21%



Current student and employment status.




Ecstasy
Cocaine
Other stimulants


Participants were recruited on the basis that they had consumed ecstasy and/or other illicit stimulants at least monthly in the past 6 months.

DRUG-RELATED HARMS AND RISKS

Drug driving 51%
Drink driving 16%



Among recent drivers, 51% reported driving a vehicle within 3 hours of consuming illicit drugs and 16% while over the legal limit of alcohol.





21% 25%

Depressant Stimulant

Percentage who reported past year non-fatal depressant and stimulant overdose.


84% 73%



2024 2025

Percentage who obtained an AUDIT score of 8 or more, indicative of past year hazardous alcohol use.

Two or more drugs 79%
Depressants and stimulants 31%
Stimulants 21%



In 2025, 79% reported using two or more drugs on the last occasion of ecstasy or related drug use: the most commonly used combination of drug classes was depressants and stimulants (31%).


OTHER BEHAVIOURS

54% 31%


Self-reported MH issue Seen a MH professional

Percentage who self-reported mental health (MH) problems and treatment seeking in the six months preceding interview.

Anxiety 69%
Depression 51%
ADHD 20%



Among those who reported a mental health problem, the three most common mental health issues were anxiety, depression and ADHD.



36%

Percentage who reported that they or someone else had tested the content and/or purity of their illicit drugs in Australia in the past year.

63% 39%

Heard of naloxone Obtained naloxone

Per cent of participants who had heard of naloxone and who had obtained naloxone in the 12 months preceding interview.

PAST 6 MONTH USE OF SELECT DRUGS

Ketamine	LSD	Hallucinogenic mushrooms/psilocybin	GHB/GBL/1,4-BD	Amyl Nitrite	Nitrous oxide (nangs)	E-cigarettes
2024 2025	2024 2025	2024 2025	2024 2025	2024 2025	2024 2025	2024 2025

*p<0.050; **p<0.010; ***p<0.001.


ECSTASY




EDRS

Ecstasy and Related Drugs Reporting System

FORM of ecstasy



Past 6 month use of ecstasy capsules, crystal, pills and powder in 2025.



Of those who had recently used any ecstasy, 34% reported weekly or more frequent use, stable from 2024 (22%).



2 Capsules



2 Pills




0.40 grams of crystal



0.50 grams of powder


Median amounts of ecstasy consumed in a 'typical' session.




Percentage who perceived ecstasy pills as being 'easy' or 'very easy' to obtain.

METHAMPHETAMINE

FORM of methamphetamine



Past 6 month use of any methamphetamine, crystal, powder and base in 2025.



Of those who had recently used any methamphetamine, 63% reported weekly or more frequent use, stable from 2024 (51%).




\$50

2024

\$50


2025

The median reported price for a point of methamphetamine crystal.




Percentage who perceived methamphetamine crystal as being 'easy' or 'very easy' to obtain.

COCAINE



Past 6 month use of any cocaine remained stable between 2024 and 2025.



Of those who had recently consumed cocaine, 12% reported weekly or more frequent use, stable from 2024 (7%).




\$350

2024

\$350


2025

The median reported price for one gram of cocaine.




Percentage who perceived cocaine as being 'easy' or 'very easy' to obtain.


CANNABIS AND/OR CANNABINOID-RELATED PRODUCTS




Past 6 month use of non-prescribed cannabis and/or cannabinoid-related products was stable between 2024 and 2025.



Of those who had recently used non-prescribed cannabis, 78% reported weekly or more frequent use, stable from 2024 (68%).



Most commonly used forms of non-prescribed cannabis, among those who reported recent use.



Percentage who perceived cannabis and/or cannabinoid-related products as being 'easy' or 'very easy' to obtain.